CRLX101单药及联合贝伐珠单抗治疗复发性卵巢癌的序贯II期临床试验
该序贯II期开放标签单臂试验评估了CRLX101单药(n=29)及联合贝伐珠单抗(n=34)治疗复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的疗效与安全性。单药组临床获益率68%、客观缓解率11%、无进展生存期4.5个月;联合组临床获益率95%、客观缓解率18%、无进展生存期6.5个月。CRLX101耐受性良好,联合贝伐珠单抗安全可行。
要点
- CRLX101单药治疗复发性卵巢癌临床获益率68%,客观缓解率11%
- 联合贝伐珠单抗后临床获益率升至95%,客观缓解率18%
- 联合方案安全可行,主要增加高血压和膀胱毒性但无严重不良事件
核心结论
- CRLX101满足了对有效且可耐受的拓扑异构酶I抑制剂的需求,并可安全联合贝伐珠单抗。
研究设计与样本
- 序贯II期开放标签单臂临床试验,评估CRLX101单药(n=29)及联合贝伐珠单抗(n=34)治疗复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌。
- 单药组允许最多3线既往化疗但排除既往拓扑异构酶I抑制剂,联合组仅纳入铂耐药且既往最多2线治疗的患者。
主要发现
- 单药组(n=29)中位治疗3个周期(范围1-16),临床获益率68%,客观缓解率11%,无进展生存期4.5个月(范围0.9-15.9个月)。
- 联合组(n=34)临床获益率95%,客观缓解率18%,无进展生存期6.5个月(范围2.8-14.4个月)。
- CRLX101耐受性良好,除恶心、疲劳和贫血外;贝伐珠单抗增加高血压发生率并定性增加膀胱毒性,但无严重不良事件。
关键数值与推荐
- 单药组CRLX101剂量为15 mg/m2静脉注射,每14天一次,28天为一周期,每2周期评估疗效。
- 联合组贝伐珠单抗剂量为10 mg/kg,第1、15天给药,28天为一周期。
临床怎么用
- 对于复发性上皮性卵巢癌患者,CRLX101单药或联合贝伐珠单抗可作为耐受性良好的治疗选择。
- 联合贝伐珠单抗时需监测高血压和膀胱毒性,但无需因严重不良事件而特别担忧。
局限性
- 研究为单臂设计,缺乏随机对照,样本量较小(单药组29例,联合组34例)。
- 联合组仅纳入铂耐药且既往治疗线数有限的患者,可能限制结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Topoisomerase-1 inhibitors are an important class of cytotoxics associated with toxicity that limits their use. CRLX101 is a novel cyclodextrin-containing polymer conjugate of camptothecin (CPT) that self-assembles into nanoparticles to deliver sustained levels of active CPT into cancer cells while substantially reducing systemic exposure. METHODS: We conducted sequential phase II, open label, single arm clinical trials to evaluate CRLX101 as a single agent (n = 29) and with bevacizumab (Bev) (n = 34). Patients (pts) had measurable recurrent epithelial ovarian, tubal or primary peritoneal cancer, that could be platinum refractory, resistant or sensitive. Cohort A (Single agent CRLX101) allowed up to 3 prior chemotherapy regimens, but no prior topo-1 inhibitors. Pts received CRLX101 15 mg/m2 IV every 14 days Q28 with response evaluation every 2 cycles. Cohort B also received Bev 10 mg/kg D1,15 Q28, and included only platinum resistant disease with up to 2 prior lines, and more rigorous eligibility criteria. RESULTS: CRLX101 was well tolerated other than nausea, fatigue and anemia. 29 pts. received a median of 3 (1-16) cycles with a clinical benefit rate (CBR) of 68% and overall response rate (ORR) of 11%. With the addition of Bev in Cohort B (n = 34), the CBR was increased to 95% and the ORR to 18%. PFS was 4.5 months (0.9 to 15.9 months) in Cohort A and 6.5 months (2.8 to 14.4 months) in Cohort B. Bev increased the incidence of hypertension and qualitatively increased bladder toxicities, but without SAEs. CONCLUSIONS: CRLX101 meets the clinical need for an effective and tolerable topoisomerase I inhibitor and can be safely combined with bevacizumab.
引用
- Krasner CN, Campos SM, Young CL, et al. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021. PMID: 34243976. doi:10.1016/j.ygyno.2021.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。